COVID-19'da protrombı̇n polı̇morfı̇zmı̇nı̇n belı̇rlenmesı̇

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to global health, societal, and economic concerns. The virus attaches to ACE2 receptors in various tissues, initiating illness. A heightened immune response plays a crucial role, and severe cases may involve a cytokine storm. The exact pathophysiological mechanisms and the impact of genetic polymorphism on disease progression remain unclear. Clinical manifestations vary, with thrombotic events linked to the genetic polymorphism Factor II G20210A in prothrombin, a key coagulation component. The aim of this study was to investigate the correlation between the G20210A polymorphism (rs1799963) of the prothrombin gene and the development of severe symptoms in individuals infected with SARS-CoV-2. A cohort comprising 100 COVID-19 patients was enrolled for this investigation, and genotyping of the prothrombin G20210A polymorphism was performed using Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. The frequency of the G20210A polymorphism was compared among the three groups, and associations with clinical outcomes were examined. The results of our study revealed that all patients exhibited the GG genotype. This observation implies that, within this particular patient cohort, the presence of the prothrombin G20210A polymorphism is not associated with the severity of COVID-19.